3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Melanoma
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Lomustine
2
Gefitinib
2
Carboplatin
2
trofosfamide
1
tozuleristide
1
entrectinib
1
Vincristine
1
Thiotepa
1
Temozolomide
1
Sunitinib
1
Radiotherapy
1
Methylprednisolone
1
Maintenance Chemotherapy
1
Magnetic Resonance Spectroscopy
1
Induction Chemotherapy
1
Etoposide
1
Erlotinib Hydrochloride
1
Diploidy
1
Dexamethasone
1
Cyclophosphamide
1
Cisplatin
1
Cholecalciferol
1
Bevacizumab
1
Adrenal Cortex Hormones
1
AZD3759
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Brain Neoplasms
×
entrectinib
×
Clear all
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled